Nikkei Biotech ONLINE – GAIA BioMedicine is now developing allogeneic natural killer (NK)-like cell therapy for solid tumors –

Our President & CEO Kazu Kuramori and senior advisor Dr. Yui Harada (Associate professor, Kyushu University), took an interview with Nikkei Biotech: “Our first clinical trial is to be started in 2021